1. Hall, AE, Chowdhury, S, Hallowell, N, et al. Implementing risk-stratified screening for common cancers: a review of potential ethical, legal and social issues. J Public Health. 2014;36(2):285–91.
Google Scholar | Crossref2. Dunlop, K, Rankin, NM, Smit, AK, et al. Acceptability of risk-stratified population screening across cancer types: qualitative interviews with the Australian public. Health Expect. 2021;24(4):1326–36.
Google Scholar | Crossref | Medline3. Hoyle, M, Anderson, R. Whose costs and benefits? Why economic evaluations should simulate both prevalent and all future incident patient cohorts. Med Decis Making. 2010;30(4):426–37.
Google Scholar | SAGE Journals4. O’Mahony, JF, van Rosmalen, J, Zauber, AG, et al. Multicohort models in cost-effectiveness analysis: why aggregating estimates over multiple cohorts can hide useful information. Med Decis Making. 2013;33(3):407–14.
Google Scholar5. Jaine, R, Kvizhinadze, G, Nair, N, et al. Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand. Lung Cancer. 2018;124:233–40.
Google Scholar | Crossref | Medline6. Naber, SK, Kuntz, KM, Henrikson, NB, et al. Cost effectiveness of age-specific screening intervals for people with family histories of colorectal cancer. Gastroenterology. 2018;154(1):105–16.e20.
Google Scholar | Crossref | Medline7. Schousboe, JT, Kerlikowske, K, Loh, A, et al. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med. 2011;155(1):10–20.
Google Scholar | Crossref | Medline | ISI8. Trentham-Dietz, A, Kerlikowske, K, Stout, NK, et al. Tailoring breast cancer screening intervals by breast density and risk for women aged 50 years or older: collaborative modeling of screening outcomes. Ann Intern Med. 2016;165(10):700–12.
Google Scholar | Crossref | Medline9. van der Meulen, MP, Kapidzic, A, van Leerdam, ME, et al. Do men and women need to be screened differently with fecal immunochemical testing? A cost-effectiveness analysis. Cancer Epidemiol Prev Biomarkers. 2017;26(8):1328–36.
Google Scholar | Crossref | Medline10. Wade, S, Weber, M, Caruana, M, et al. Estimating the cost-effectiveness of lung cancer screening with low-dose computed tomography for high-risk smokers in Australia. J Thorac Oncol. 2018;13(8):1094–105.
Google Scholar | Crossref | Medline11. Cenin, DR, Naber, SK, de Weerdt, AC, et al. Cost-effectiveness of personalized screening for colorectal cancer based on polygenic risk and family history. Cancer Epidemiol Prev Biomarkers. 2020;29(1):10–21.
Google Scholar | Crossref | Medline12. Goossens, N, Singal, AG, King, LY, et al. Cost-effectiveness of risk score–stratified hepatocellular carcinoma screening in patients with cirrhosis. Clin Translat Gastroenterol. 2017;8(6):e101.
Google Scholar | Crossref | Medline13. Gray, E, Donten, A, Karssemeijer, N, et al. Evaluation of a stratified national breast screening program in the United Kingdom: an early model-based cost-effectiveness analysis. Value Health. 2017;20(8):1100–9.
Google Scholar | Crossref | Medline14. Snowsill, T, Yang, H, Griffin, E, et al. Low-dose computed tomography for lung cancer screening in high risk populations: a systematic review and economic evaluation. Health Technol Assess. 2018;22(69).
Google Scholar | Crossref | Medline15. ten Haaf, K, Tammemägi, MC, Bondy, SJ, et al. Performance and cost-effectiveness of computed tomography lung cancer screening scenarios in a population-based setting: a microsimulation modeling analysis in Ontario, Canada. PLoS Med. 2017;14(2):e1002225.
Google Scholar | Crossref | Medline16. Tomonaga, Y, Ten Haaf, K, Frauenfelder, T, et al. Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking—a modelling study. Lung Cancer. 2018;121:61–9.
Google Scholar | Crossref | Medline17. Toumazis, I, Tsai, EB, Erdogan, SA, et al. Cost-effectiveness analysis of lung cancer screening accounting for the effect of indeterminate findings. JNCI Cancer Spectr. 2019;3(3):pkz035.
Google Scholar | Crossref | Medline18. Vilaprinyo, E, Forne, C, Carles, M, et al. Cost-effectiveness and harm-benefit analyses of risk-based screening strategies for breast cancer. PLoS One. 2014;9(2):e86858.
Google Scholar | Crossref | Medline | ISI19. Arnold, M, Pfeifer, K, Quante, AS. Is risk-stratified breast cancer screening economically efficient in Germany? PLoS One. 2019;14(5):e0217213.
Google Scholar | Crossref | Medline20. Drummond, MF, Sculpher, MJ, Claxton, K, et al. Methods for the Economic Evaluation of Health Care Programmes. Oxford (UK): Oxford University Press; 2015.
Google Scholar21. Torrance, GW. Framing and designing the cost-effectiveness analysis. In: Gold, MR, Siegel, JE, Russell, LB, Weinstein, MC, eds. Cost-Effectivenessn in Health and Medicine. Oxford (UK): Oxford University Press; 1996. p 54–81.
Google Scholar22. Stinnett, AA, Mullahy, J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998;18(2 suppl):S68–S80.
Google Scholar | SAGE Journals | ISI23. Gold, MR, Siegel, JE, Russell, LB, et al. Cost-Effectiveness in Health and Medicine. Oxford (UK): Oxford University Press; 1996.
Google Scholar24. Pedersen, K, Burger, EA, Nygård, M, et al. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: the value of stratifying guidelines. Eur J Cancer. 2018;91:68–75.
Google Scholar | Crossref | Medline25. Lew, J-B, Simms, KT, Smith, MA, et al. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program. Lancet Public Health. 2017;2(2):e96–107.
Google Scholar | Crossref | Medline26. Pashayan, N, Morris, S, Gilbert, FJ, et al. Cost-effectiveness and benefit-to-harm ratio of risk-stratified screening for breast cancer: a life-table model. JAMA Oncol. 2018;4(11):1504–10.
Google Scholar | Crossref | Medline27. McLeod, M, Kvizhinadze, G, Boyd, M, et al. Colorectal cancer screening: how health gains and cost-effectiveness vary by ethnic group, the impact on health inequalities, and the optimal age range to screen. Cancer Epidemiol Prev Biomarkers. 2017;26(9):1391–400.
Google Scholar | Crossref | Medline28. Callender, T, Emberton, M, Morris, S, et al. Polygenic risk-tailored screening for prostate cancer: a benefit–harm and cost-effectiveness modelling study. PLoS Med. 2019;16(12):e1002998.
Google Scholar | Crossref | Medline29. Wilson, EC, Usher-Smith, JA, Emery, J, et al. A modeling study of the cost-effectiveness of a risk-stratified surveillance program for melanoma in the United Kingdom. Value Health. 2018;21(6):658–68.
Google Scholar | Crossref